The invention relates to an isolated antibody or a fragment thereof that binds to the SKECF peptide of the sST2 protein. In particular, the invention relates to a short variable fragment of an antibody (scFv) and to a human antibody with affinity for the sST2 molecule, to nucleic acids encoding the same, to the pharmaceutical compositions containing the same, and to the use thereof to treat inflammatory diseases, such as ulcerative colitis.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
2.
COMPOUNDS DERIVED FROM DIHYDROPIRIDINES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHOD OF TREATMENT OF MUSCLE DISORDERS COMPRISING ADMINISTRATION OF SAID COMPOSITIONS
The invention of the present application relates to compounds derived from tetrahydrofuran [3,4-b]pyridine-3-carboxylate, pharmaceutical compositions comprising said compounds and a method of prevention and treatment of muscle disorders comprising administration of said pharmaceutical compositions for recovery of muscular function in a subject in need thereof.
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
A61K 31/4355 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'oxygène comme hétéro-atome du cycle
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
3.
METHOD FOR SIMULTANEOUSLY DETECTING AND IDENTIFYING MULTIPLE SPECIES OF MUSSELS OF THE GENUS MYTILUS AND ASSOCIATED OLIGONUCLEOTIDES/PROBES
MytilusMytilus and associated oligonucleotides/probes, including their first-generation hybrids and hybrids from other generations, using a polymerase chain reaction (PCR)-based multi-locus method and a subsequent step with the High Resolution Melting (HRM) technique using a pool of specific primers. The invention also relates to a kit and the use thereof.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes
4.
REAGENT, PHARMACEUTICAL COMPOSITION AND METHODS FOR DETECTION, EVALUATING PROGRESSION AND TREATMENT OF DISEASES ASSOCIATED WITH β-AMYLOID PLAQUES
The present invention relates to the technical field of nanotechnology and pharmaceutics, in particular to a reagent and a pharmaceutical composition containing gold nanorods conjugated with D1 and Angiopep-2 peptides, and methods for detection, diagnosis, evaluating progression, and treatment of diseases related to beta-amyloid plaques, such as Alzheimer's disease. Surprisingly, with the reagent and pharmaceutical composition of the present invention, a dose of gold per kg of body weight well below those previously reported is required, hence the applications thereof are more economical, in addition to decreasing the likelihood of toxic effects, thanks to the low doses required to exert their function.
A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p. ex. un ion inorganique complexé avec l’ingrédient actif
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
The present invention relates to pharmaceutical compositions and methods for obtaining said pharmaceutical compositions comprising a conditioned culture medium of human mesenchymal stem cells and/or a combination of trophic factors expressed by human mesenchymal stem cells, and a polymeric matrix of hyaluronic acid. The present invention also relates to methods for preventing and/or treating patients having pathologies that generate tortuous vessels, or complications from the appearance of tortuous vessels, such as varicose veins, psoriasis, hemorrhoids, rosacea, acne, crystal skin, atopic dermatitis, among others.
2-H), AND SYNTHESIS METHOD THEREOF, HAVING A BIFUNCTIONAL PROPERTY FOR SIMULTANEOUSLY PHOTOOXIDISING ARSENIC III AND ADSORBING ARSENIC V IN A SINGLE STEP, IN ORDER TO REMOVE THIS ELEMENT FROM SURFACE AND/OR UNDERGROUND REAL WATER
2222-H operates in suspension, which makes it possible to perform the dual function of photooxidising As(III) to As(V) and simultaneously adsorbing the generated As(V), from surface and/or underground real water.
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
C02F 1/30 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par irradiation
C02F 1/72 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par oxydation
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
B01J 21/06 - Silicium, titane, zirconium ou hafniumLeurs oxydes ou hydroxydes
B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
7.
METHOD AND SYSTEM FOR NAVIGATING AN AUTONOMOUS VEHICLE IN AN OPEN-PIT SITE
Method and system for navigating an autonomous vehicle in an open-pit site. The method comprises: acquiring a plurality of observations (72) and odometry information, from a plurality of discrete poses while driving; accessing a topological map (10) of the open-pit site comprising intersections and segments; accessing an observational map (20) of the open-pit site with past observations comprising surroundings information associated with an intersection or a segment; processing past observations, acquired observations and odometry information, applying a particle filtering technique and Gaussian processes for modelling observations acquired from discrete poses as a continuous variable and estimating the current pose and according to a current direction of movement, statistically predicting a next pose of the autonomous vehicle; commanding the autonomous vehicle (30) via actuators controlled by the processor unit (33), based on detecting whether the autonomous vehicle (30) is in a segment or in an intersection, and respectively command the autonomous vehicle (30) a moving-forward instruction to traverse the segment or a steering instruction to take a subsequent segment.
+-polycarboxylate grafted few-layer graphene oxide including perovskite type nanoparticles for filler in polymeric matrices, in direct and reverse osmosis membranes, in lithium batteries, among others. The material is obtained by a method comprising the step of: preparation of a composite material having polymers with mono- or di-acid groups covalently bonded to graphene; optionally further comprising the preparation of a composite material with graphene covalently bonded to polymers having mono- or di-acid groups that have been replaced by lithium ion; and optionally further comprising the preparation of a composite material with graphene covalently bonded to polymers having mono- or di-acid groups that have been replaced by lithium ion in addition to grafted nanoparticles, including nanoparticles perovskite type.
The invention refers to a method and a system for determining and selecting rock breaking target poses, the method comprising acquiring images and range data of rock elements in a pile of material to carry out a segmentation process using an watershed method adapted for surfaces structured as point clouds, that allows to accurately identify rock elements within the pile of material, and the system comprising a plurality of sensors configured to acquire images and range data of rock elements in a pile of material and a processor operatively connected to said plurality of sensors to receive and process the sensor data and configured to carry on the steps of said method.
B28D 1/26 - Travail de la pierre ou des matériaux analogues p. ex. briques, béton, non prévu ailleursMachines, dispositifs, outils à cet effet par outils à percussion, p. ex. par ciseaux ou autres outils ayant une arête coupante
G01S 17/06 - Systèmes déterminant les données relatives à la position d'une cible
G01S 17/88 - Systèmes lidar, spécialement adaptés pour des applications spécifiques
G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
10.
AUTOANTIGENIC PEPTIDES (CALVICIFIV), PRESENTED BY TOLEROGENIC DENTRITIC CELLS, USEFUL FOR THE PERSONALIZED TREATMENT OF RHEUMATOID ARTHRITIS
The present invention provides an immunomodulatory composition useful for treating or preventing joint damage comprising at least a set of peptides possessing an amino acid sequence having at least 80%, 85% and 90% sequence identity with the peptides corresponding to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 and a method for the treatment or prevention of joint damage comprising the steps of a) extract monocytes from a patient with a rheumatological disease; b) culture the monocytes extracted in the previous step in AIM-V medium with GM-CSF and IL-4; c) wash the monocytes and add dexamethasone; d) load the tDCs with the immunomodulatory composition comprising autoantigenic peptides; e) add MPLA; and f) incorporate the tDCs loaded with autoantigenic peptides into the patient. The present invention includes methods for the treatment or prevention of rheumatological disease comprising a wide range of tDCs performed by different protocols.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
Candida albicans, Streptococcus mutans, Staphylococcus aureus and Aggregatibacter actinomycetemcomitansCandida albicans, Streptococcus mutans, Staphylococcus aureus and Aggregatibacter actinomycetemcomitans. Surprisingly, the composition for a denture adhesive comprising copper nanoparticles (CuNPs) not only shown excellent antimicrobial properties, but also improved adhesive properties in comparison with other denture adhesives existing currently in the market, which do not contain said CuNPs.
A61K 6/884 - Préparations pour la fabrication de dents artificielles, l’obturation ou le recouvrage des dents comprenant des résines naturelles ou synthétiques
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
12.
HISTATIN-1 FORMULATION FOR THE TREATMENT, REPAIR OR REGENERATION OF BONE TISSUE IN A SUBJECT
The present invention relates to a formulation or composition for the treatment, repair, formation or regeneration of bone tissue in a subject, comprising Histatin-1 or its derivatives. The present invention also relates to a biomaterial comprising Histatin-1 or its derivatives in a biocompatible material, and a method for the treatment, repair, formation or regeneration of bone tissues in a subject comprising administering to the subject a therapeutically effective amount of Histatin-1 or its derivatives.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 19/00 - Médicaments pour le traitement des troubles du squelette
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
Pilgerodendron uviferumPilgerodendron uviferum) which is encapsulated in nanoparticles of chitosan with sodium tripolyphosphate, a gel comprising the same, methods for producing the essential oil, the composition with antimicrobial activity and the gel comprising the same, and the use of Guaitecas Cypress essential oil and the composition comprising the same for the treatment of acne and periodontal disease.
A01N 37/08 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant des groupes carboxyliques, ou leurs thio-analogues, liés directement par l'atome de carbone à un cycle cycloaliphatiqueLeurs dérivés
A01N 37/42 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant dans le même squelette carboné un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome de carbone ne comportant que deux liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. acides cétocarboxyliques
A01N 37/44 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant au moins un groupe carboxylique ou un thio-analogue, ou un de leurs dérivés, et un atome d'azote lié au même squelette carboné par une liaison simple ou double, cet atome d'azote ne faisant pas partie d'un dérivé ou d'un thio-analogue d'un groupe carboxylique, p. ex. acides aminocarboxyliques
14.
METHOD FOR SIMULTANEOUS DETECTION AND QUANTIFICATION OF LISTERIA MONOCYTOGENES, SALMONELLA SPP., AND SHIGA TOXIN-PRODUCING ESCHERICHIA COLI (STEC)
The invention refers to a method for simultaneous detection and quantification of Listeria monocytogenes, Salmonella spp. and Shiga toxin-producing Escherichia coli (STEC), from any kind of sample related to food production, including complex food matrices such as fish, meat, or fruit; or simple matrices such as water, or food contact surfaces. The method of invention allows specific quantification of the above-mentioned pathogens simultaneously thanks to specificity of designed primers for the qPCR reaction. It is also highly reliable because the method includes a system to adequately control the quantification of pathogens within the matrix. This system comprises the inoculation of samples with a known concentration of a transformed microorganism (host) carrying a chimeric sequence, acting as an internal control host for the whole process.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
15.
METHOD FOR SIMULTANEOUS DETECTION AND QUANTIFICATION OF LISTERIA MONOCYTOGENES, SALMONELLA SPP., AND SHIGA TOXIN-PRODUCING ESCHERICHIA COLI (STEC)
The invention refers to a method for simultaneous detection and quantification of Listeria monocytogenes, Salmonella spp. and Shiga toxin-producing Escherichia coli (STEC), from any kind of sample related to food production, including complex food matrices such as fish, meat, or fruit; or simple matrices such as water, or food contact surfaces. The method of invention allows specific quantification of the above-mentioned pathogens simultaneously thanks to specificity of designed primers for the qPCR reaction. It is also highly reliable because the method includes a system to adequately control the quantification of pathogens within the matrix. This system comprises the inoculation of samples with a known concentration of a transformed microorganism (host) carrying a chimeric sequence, acting as an internal control host for the whole process.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
16.
ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
PONTIFICIA UNIVERSIDAD DE CATÓLICA DE CHILE (Chili)
Inventeur(s)
Ocaranza Geraldino, María Paz
Kogan, Marcelo Javier
Lavandero González, Sergio Alejandro
Chiong Lay, Mario Martín
Abrégé
The present invention provides an angiotensin-(1-9) analog, particularly an angiotensin-(1-9) peptide synthesized from D-amino acids. This invention further involves the inversion of the original sequence of angiotensin-(1-9). This analog possesses an increased stability and maintains the biological activity of angiotensin-(1-9). Another embodiment of this invention comprises pharmaceutical compositions containing said analog and their use in the treatment of cardiovascular diseases, tissue remodeling in kidney, brain, and also the induction of cardioprotection.
The invention relates to the pharmaceutical industry, particularly to the pharmaceutical industry related to biological drugs, biomacromolecules, biopharmaceuticals, or biologics. More particularly, the invention relates to a method for the manufacture of a highly controlled and stable dosage form with mucoadhesive properties for buccal administration of biologics such as lymphokines, hormones, hematopoietic factors, growth factors, antibodies, enzymes, inhibitors, vaccines, DNA, and RNA derivatives, among others. Based on inkjet printing, the invention uses inks comprising the biologic(s) included in a nanosystem, particularly in polymeric nanoparticles.
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Escherichia coli (STEC), the formulation comprising: one or more chimeric proteins derived wholly or in part from OmpT and Hes proteins of STEC; and at least one physiologically or pharmaceutically acceptable excipient, carrier and/or diluent.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A new and distinct variety of nectarine tree named ‘Andes Nec-6’ with medium vigor, which produces a nectarine with a slow pulp softening rate during the last two weeks before a commercial harvest, the nectarine has a high postharvest life potential, the nectarine is broad elliptic, moderately asymmetric, the nectarine has white flesh and the surface of its skin is cream yellow with 70 to 80% of its skin being covered by mottled red blush, and the nectarine has a balanced acid/sweet flavor.
Described is a targeted gene therapy for use in the delay or treatment of a symptomatic stage of aging and/or age-related disease in a subject, in particular to maintain or restore endoplasmic reticulum proteostasis. The gene therapy comprises the administration of a therapeutically effective amount of a pharmaceutically acceptable composition comprising X-box binding protein 1 (XBP1) or an agent that stimulates neuronal expression of XBP1 in the brain of the subject.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Aspects of the present disclosure generally relate to immunotherapy, cancer vaccines and the treatment of cancer diseases. By way of example, the present disclosure relates to novel combined with an immunologically effective amount of adjuvant, for treating cancer in a subject methods of generating such formulations, and methods of use thereof.
NATURAL SURFACTANTS COMPRISING SOLUBLE NANOCOMPLEXES OF QUINOA PROTEINS/ANIONIC POLYSACCHARIDES (ALGINATE) AND CATIONIC POLYSACCHARIDES (CHITOSAN) FOR USE IN FOODS AND COSMETICS
The present invention relates to: natural surfactants comprising soluble nanocomplexes of quinoa proteins/anionic polysaccharides (alginate) and cationic polysaccharides (chitosan); a production method for same; food emulsions comprising same, when edible vegetable oils are used as a fatty phase,; and the use thereof in low-calorie food products such as sauces, creams and dressings.
A23L 29/206 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale
A23L 29/256 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale à base d'algues, p. ex. alginates, agar-agar ou carraghénane
The present invention relates to the use of regenerative medicine in livestock farming, in particular to regenerative medicine for the care of livestock, and even more particularly to regenerative medicine in the care of milk-producing animals, including cattle. Specifically, the invention concerns a foetal mesenchymal stem cell (MSC) composition of allogenic origin, a treatment method and the use thereof in mastitis in milk-producing animals, including cattle, suffering from mastitis, to immunostimulate the animal, the MSC coming from foetal bovine adipose tissue. The composition can be administered via the intramammary route, exercising an immunomodulatory effect on the inflammatory response and strengthening antimicrobial activity against mastitis-causing pathogens in milk-producing animals with mastitis, thereby becoming an alternative to replacing and/or supplementing the use of antibiotics.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 15/14 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs pour les troubles de la lactation, p. ex. galactorrhée
The present invention concerns a new antimicrobial denture adhesive composition useful to be used for fixing dentures, which includes copper nanoparticles (CuNPs) that provides antimicrobial properties against dental pathogens such as Candida albicans, Streptococcus mutans, Staphylococcus aureus and Aggregatibacter actinomycetemcomitans. Surprisingly, the composition for a denture adhesive comprising copper nanoparticles (CuNPs) not only shown excellent antimicrobial properties, but also improved adhesive properties in comparison with other denture adhesives existing currently in the marked, which do not contain said CuNPs.
A61K 6/70 - Préparations pour la technique dentaire comprenant des additifs inorganiques
A61K 6/887 - Composés obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A01N 55/02 - Biocides, produits repoussant ou attirant les animaux nuisibles ou régulateurs de croissance des végétaux, contenant des composés organiques comportant des éléments autres que le carbone, l'hydrogène, les halogènes, l'oxygène, l'azote et le soufre contenant des atomes de métal
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
25.
HIGHLY ELECTRICAL CONDUCTIVE COMPOSITE MATERIAL BASED ON GRAPHENE-LITHIUM POLYCARBOXYLATE-NANOPARTICLES
Herein presented is a high electrical conductivity, uniform, material based on nanoparticles-Li+-polycarboxylate grafted few-layer graphene oxide including perovskite type nanoparticles for filler in polymeric matrices, in direct and reverse osmosis membranes, in lithium batteries, among others. The material is obtained by a method comprising the step of: preparation of a composite material having polymers with mono- or di-acid groups covalently bonded to graphene; optionally further comprising the preparation of a composite material with graphene covalently bonded to polymers having mono- or di-acid groups that have been replaced by lithium ion; and optionally further comprising the preparation of a composite material with graphene covalently bonded to polymers having mono- or di-acid groups that have been replaced by lithium ion in addition to grafted nanoparticles, including nanoparticles perovskite type.
H01B 1/06 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisésEmploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques
H01B 1/12 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisésEmploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques substances organiques
C08L 51/10 - Compositions contenant des polymères greffés dans lesquels le composant greffé est obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carboneCompositions contenant des dérivés de tels polymères greffés sur des substances inorganiques
26.
LAMINAR ZINC HYDROXIDE ORGANIC-INORGANIC NANOCOMPOSITES FOR USE IN THE REMOVAL AND DEGRADATION OF DYES FROM TEXTILE EFFLUENTS OR ORGANIC SUBSTANCES
The present invention relates to a method for removing dyes from textile effluents and other organic substances using nanocomposites based on zinc hydroxides and carboxylic acids capable of adsorbing and degrading. More specifically, the present invention consists of a method to generate new zinc hydroxide-based materials, which allows removal and degradation of methylene blue and other organic compounds from wastewater from industrial effluents, particularly those from textile industry.
B01J 31/04 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques contenant des acides carboxyliques ou leurs sels
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
The present invention relates to an alternative process for the recovery of metals, such as copper and zinc, in addition to cyanide, from cyanide-bearing solutions present in gold and silver recovery mining processes in a more efficient way than at present. The process includes different membrane separation processes and the use of metal sulphide precipitation reactions, which is capable of generating marketable high-concentration metal sulphide products and of recovering cyanide in a concentrated solution more efficiently than current alternatives.
C22B 3/22 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés physiques, p. ex. par filtration, par des moyens magnétiques
C22B 3/44 - Traitement ou purification de solutions, p. ex. de solutions obtenues par lixiviation par des procédés chimiques
28.
HISTATIN-1 FORMULATION FOR THE TREATMENT, REPAIR OR REGENERATION OF BONE TISSUE IN A SUBJECT
The present invention relates to a formulation or composition for the treatment, repair, formation or regeneration of bone tissue in a subject, comprising Histatin-1 or its derivatives. The present invention also relates to a biomaterial comprising Histatin-1 or its derivatives in a biocompatible material, and a method for the treatment, repair, formation or regeneration of bone tissues in a subject comprising administering to the subject a therapeutically effective amount of Histatin-1 or its derivatives.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Seed germ for botanical purposes; Nectarine seeds; Fresh seeds for agricultural use; Fresh nectarines. Scientific research and technology development in relation to the following fields: Fruit growing industry, Especially, Development of new nectarine varieties.
30.
ONION SKIN EXTRACT WITH PROPERTIES THAT PROTECT THE GASTROINTESTINAL MUCOSA AGAINST DAMAGE INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS OR BY ALCHOL, PHARMACEUTICAL COMPOSITION OR FOOD COMPRISING IT, METHOD OF OBTAINMENT, AND USE TO PREVENT, TREAT AND/OR MITIGATE THE ADVERSE EFFECTS OF NSAIDS OR ALCOHOL
An onion skin extract with properties that protect the gastrointestinal mucosa against damage induced by non-steroidal anti-inflammatory drugs or by alcohol, pharmaceutical composition or food comprising it, method of obtainment, and use to prevent, treat and/or mitigate the adverse effects of NSAIDS or alcohol.
A61K 36/8962 - Allium, p. ex. oignon, poireau, ail ou ciboulette
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A23L 19/00 - Produits à base de fruits ou de légumesLeur préparation ou leur traitement
A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
31.
AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others
The present invention presents a sequence of the AAV/UPR-plus virus, a genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's and Huntington's diseases, among others, as presented in the in vitro studies shown in FIG. 14/17.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
32.
MIXTURE OF FUNGAL BIOCONTROLLERS FOR CONTROLLING FUNGI THAT CAUSE DEAD ARM OF GRAPEVINE
A biocontrol composition for phytopathogenic fungi, having Trichoderma harzianum, Clonostachys rosea and an agronomically appropriate vehicle is disclosed. Also disclosed is a method for preventing and controlling fungal diseases in plants, by using the composition on a plant susceptible to developing a fungal infection.
The present invention provides an immunomodulatory composition useful for the treatment or prevention of joint damage comprising at least a set of peptides possessing an amino acid sequence having at least 80%, 85% and 90% sequence identity with the peptides corresponding to SEQ ID No.1, SEQ ID No 2, SEQ ID No.3 and SEQ ID No.4 and a method for the treatment or prevention of joint damage comprising the steps of a) extract monocytes from a patient with a rheumatological disease; b) culture the monocytes extracted in the previous step in AIM-V medium with GM-CSF and IL-4; c) wash the monocytes and add dexamethasone; d) load the tDCs with the immunomodulatory composition comprising autoantigenic peptides; e) add MPLA; and f) incorporate the tDCs loaded with autoantigenic peptides into the patient. The present invention includes methods for the treatment or prevention of rheumatological diseasecomprising a wide range of tDCs performed by different protocols.
Vaccines of preferential administration via mucous membranes, for the control of viral diseases generated by infectious agents that use heparan sulfate (HS) as a cellular receptor consisting of an immunogenic formulation for veterinary use, comprising an antigen whose cellular receptor is heparan sulfate (HS), a vehicle for oral, intranasal or parenteral administration, wherein said vehicle corresponds to D-glucosamine and functionalized N-acetyl-D-glucosamine biopolymers, with sulfur atoms, and/or functionalized chitosan biopolymer, with sulfur atoms, and where the antigen is microencapsulated by said types of functionalized biopolymers.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12P 19/04 - Polysaccharides, c.-à-d. composés contenant plus de cinq radicaux saccharide reliés entre eux par des liaisons glucosidiques
C12P 19/18 - Préparation de composés contenant des radicaux saccharide préparés par action d'une transférase glycosylique, p. ex. alpha-, bêta- ou gamma-cyclodextrines
A new and distinct variety of nectarine tree named ‘Andes Nec-5’ with high vigor, which produces a nectarine with a slow pulp softening rate during the last two weeks before a commercial harvest, the nectarine has a high postharvest life potential, the nectarine is round, symmetrical, it is white in flesh color and most of the nectarine surface is covered by 90 to 100% red blush, and the nectarine has a balanced acid/sweet flavor.
The present invention relates to a water-soluble film comprising alginate combined with quinoa or snail slime and optionally a plant extract, such as matico. The invention also relates to the nanoencapsulation of natural extracts in alginate–quinoa and chitosan–quinoa nanocomplexes, and to the water-soluble film for cosmetic use that comprises alginate combined with quinoa or snail slime and is loaded with bioactive agents and extracts nanoencapsulated in soluble alginate–quinoa and chitosan–quinoa complexes. The invention further relates to a method for producing the water-soluble films comprising alginate combined with quinoa or snail slime, and to the uses thereof. Lastly, the invention also relates to a method for nanoencapsulating natural extracts and subsequently incorporating same into the film of the present application.
A61K 8/97 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base d’algues, de champignons, de lichens ou de plantesCosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de leurs dérivés
The present invention consists of functionalised NDs (fNDs) -housing stable fluorescent colour centres- with a bifunctional peptide capable of recognising extracellular amyloid-beta aggregates (Aß) and the accumulation thereof, which is considered the true cause of neuronal damage and cognitive decline in AD. fNDs are not cytotoxic and enable ultrasensitive detection (using picomolar Nd concentrations) of amyloid fibrils and amyloid aggregates. Moreover, the fluorescence of fNDs is more stable than the common colour markers used to dye Aß, such as Thioflavin T.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Plant and fruit seeds; plant, fruit, and agricultural seeds and bulbs; raw seeds for agricultural use, all of the aforementioned products related to plums; fresh plums Scientific research and technological development services related to the fruit sector, namely, the development of new varieties of plums
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Seed germ for botanical purposes; Seeds and bulbs; Unprocessed seeds for agricultural purposes, all the aforesaid goods relating to plums; Fresh plums. Scientific research and technological development in the fruit sector, in particular development of new varieties of plums.
40.
PROBE AND SYSTEM FOR MONITORING AN ENVIRONMENTAL VARIABLE IN AN ACID MEDIUM
The present invention relates to the field of metrology and testing, more particularly to the research or analysis of materials by determination of their physical or chemical properties, and specifically provides a probe for monitoring an environmental variable in an acid medium, characterised in that it comprises: a tubular casing having a lower end and an upper end; a point joined to the lower end of said tubular casing, said point having an inner space; a sensor of said environmental variable, housed in said inner space of said point; a processor, operationally coupled to said sensor and positioned in the interior of said tubular casing; and a source of electricity operationally coupled to said processor; wherein said processor is configured to control said sensor and obtain measurements from said sensor and store said measurements; and wherein said sensor enables the measurement of said environmental variable without being placed in direct contact with said acid medium. According to the foregoing description, it is possible to obtain a probe that makes it possible to monitor an environmental variable in an acid medium, overcoming the deficiencies of the prior art.
G01K 1/02 - Moyens d’indication ou d’enregistrement spécialement adaptés aux thermomètres
G01K 1/08 - Dispositifs de protection, p. ex. étuis
G01K 1/10 - Dispositifs de protection, p. ex. étuis pour prévenir les dommages d'origine chimique
G01K 1/14 - SupportsDispositifs de fixationDispositions pour le montage de thermomètres en des endroits particuliers
G01K 13/00 - Thermomètres spécialement adaptés à des fins spécifiques
G01K 13/02 - Thermomètres spécialement adaptés à des fins spécifiques pour mesurer la température de fluides en mouvement ou de matériaux granulaires capables de s'écouler
G01K 7/00 - Mesure de la température basée sur l'utilisation d'éléments électriques ou magnétiques directement sensibles à la chaleur
G01K 7/02 - Mesure de la température basée sur l'utilisation d'éléments électriques ou magnétiques directement sensibles à la chaleur utilisant des éléments thermo-électriques, p. ex. des thermocouples
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
Peptide sequence of a guide protein for the production of a peptide of interest, an expression vector, a host cell, and a method for the production of a peptide of interest
A peptide sequence of a guide protein for the production of a peptide of interest; a peptide sequence that has a similarity of at least 90% to SEQ. ID. NO 1; a nucleotide sequence encoding the guide protein; an expression vector comprising the nucleotide sequence; a host cell that expresses a fusion protein comprising a peptide of interest; a method of production of a peptide of interest, comprising the steps of A) constructing an expression vector; B) inserting the expression vector into a host cell; C) expressing the fusion protein, culturing the host cell in a culture medium; D) recovering the accumulated fusion protein in the host cell; E) cleaving the fusion protein; F) purifying the peptide of interest.
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/67 - Méthodes générales pour favoriser l'expression
42.
Green methodology to create polymeric nanocarriers containing hydrophilic low molecular-weight drugs and providing a very high drug loading and a very high prolonged release
In one aspect, provided herein is a nanocarrier composition for formulating a hydrophilic and aromatic low molecular-weight drug (HALMD), the composition comprising: an aromatic polymer; and a hydrophilic and aromatic low molecular-weight drug (HALMD);
wherein the aromatic polymer has a positive or negative charge or is a zwitterion, and the hydrophilic and aromatic low molecular-weight drug (HALMD) has an opposing positive or negative charge or is a zwitterion; and wherein the composition has a size of between 50-400 nm and optionally, a zeta potential of from +100 to −100 mV. A method for preparing the nanocarrier composition, as well as pharmaceutical compositions and therapeutic uses thereof, are also disclosed.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Escherichia coliEscherichia coli (STEC), the formulation comprising: one or more chimeric proteins derived wholly or in part from OmpT and Hes proteins of STEC; and at least one physiologically or pharmaceutically acceptable excipient, carrier and/or diluent.
The invention discloses an in-situ method for reducing hydraulic conductivity and generating the precipitation of insoluble minerals in an underground aquifer which is affected by seepage of surface water or by seepage of water from a mining tailings tank, comprising at least the following steps: (a) providing a sulphate-reducing bacteria-enriched microbial culture adapted to the underground water of the aquifer to be treated, (b) injecting an enriched microbial culture into the underground aquifer, (c) injecting an electron and nutrient donor for reducing bacteria-enriched microbal culture and one or more metal cations that favour the precipitation of insoluble minerals, and (d) allowing the microorganims to multiply and colonise the solid material of the underground aquifer, reducing the hydraulic permeability of the underground aquifer and causing the precipitation of insoluble minerals in the solid material of the underground aquifer.
The present invention refers to nanoparticles containing interferon encapsulated with chitosan and cyclodextrin and a pharmaceutical composition containing them, specially designed to be used by a non-invasive alternative administration route to a patient, in order to improve the therapeutic efficiency of treatments with interferons, particularly those needing that said molecule reaches the target organ of interest directly.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The invention relates to an assistive method for the teleoperation of vehicles in tunnels, for example mining tunnels, which comprises the steps of: (a) providing a teleoperation interface, which comprises a unit with a console that allows a teleoperator to give teleoperation commands and a screen that allows the teleoperator to view sensory information regarding a machine and its environment; (b) providing a perception-motor module for obtaining perceptual information regarding the environment, which information is obtained from sensors on the machine, and for executing commands from the assistive module, the commands being converted into signals that actuators of the vehicle execute to carry out a task predefined by the teleoperator; and (c) providing an assistive module that implements an assistive method and which utilises the teleoperation commands and the sensory information to give optimised commands for the movement of the machine, wherein the assistive module comprises the steps of: (i) acquiring variables through the perception-motor module, (ii) providing a route optimisation module, and (iii) providing a command publication module consisting in sending the calculated commands to the perception-motor module.
G05D 1/00 - Commande de la position, du cap, de l'altitude ou de l'attitude des véhicules terrestres, aquatiques, aériens ou spatiaux, p. ex. utilisant des pilotes automatiques
G05D 1/02 - Commande de la position ou du cap par référence à un système à deux dimensions
G01S 17/88 - Systèmes lidar, spécialement adaptés pour des applications spécifiques
G01S 17/931 - Systèmes lidar, spécialement adaptés pour des applications spécifiques pour prévenir les collisions de véhicules terrestres
Aspects of the present disclosure generally relate to immunotherapy, cancer vaccines and the treatment of cancer diseases. By way of example, the present disclosure relates to novel combined with an immunologically effective amount of adjuvant, for treating cancer in a subject methods of generating such formulations, and methods of use thereof.
Described is a targeted gene therapy for use in the delay or treatment of a symptomatic stage of aging and/or age-related disease in a subject, in particular to maintain or restore endoplasmic reticulum proteostasis. The gene therapy comprises the administration of a therapeutically effective amount of a pharmaceutically acceptable composition comprising X-box binding protein 1 (XBP1) or an agent that stimulates neuronal expression of XBP1 in the brain of the subject.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention relates to a system for the production of carbon nanotubes from carbonaceous matter, preferably, plastic waste and solar energy; Method of production.
F24S 50/20 - Agencements pour commander les collecteurs de chaleur solaire pour le suivi
F24S 23/30 - Agencements pour concentrer les rayons solaires pour les collecteurs de chaleur solaire avec des lentilles
F24S 30/48 - Agencements pour mouvoir ou orienter des modules de collecteurs de chaleur solaire pour le déplacement en rotation avec trois axes de rotation ou plus ou avec de multiples degrés de liberté
The invention relates to a magneto-centrifugal flotation cell for ore concentration which reduces water consumption. A disadvantage of conventional flotation cells is the use of a large amount of water, some flotation cells requiring at least 60% water. The present invention uses ore pulp with increased density and viscosity, owing to the application of an axial magnetic field, wherein the Lorentz force, which is the force exerted by an electromagnetic field that receives a charged particle or an electrical current, can be used. The solution is a cell which, in addition to the forces that usually act on conventional flotation cells, uses external forces which, in principle, produce synergy in the separation of ore particles that have different gravitational and magnetic properties.
The present invention relates to the medical industry. In particular, it is related to a polyvinyl chloride polymer (PVC) functionalized for medical use, which is flexible and compatible with blood. Specifically, this invention is related to a biomolecule-functionalized PVC and its production method, in order to produce a flexible and blood-compatible polymer for medical use.
The present invention related to a pharmaceutical composition for the treatment of chronic addiction to psychoactive substances and/or the prevention of relapse to an addiction to psychoactive substances, said composition comprising secretome and/or exosomes derived from preconditioned mesenchymal stem cells; and the use of said composition for the treatment of addiction to psychoactive substances and prevention of relapse to said addiction.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 25/32 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance à l'alcool
A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
A61P 25/34 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance au tabac
A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
53.
VIRUS AAV/IGF2, GENETIC TREATMENT METHOD AND USE THEREOF IN PROTEIN MISFOLDING-RELATED DISEASES, SUCH AS HUNTINGTON'S DISEASE
The invention relates to the expression of two molecules in viral vectors AAV/IGF2-HA and AAV/IGF2, the associated method and use thereof in the amelioration of protein misfolding-related diseases, such as Huntington's disease, as presented in the in vivo models in FIG. 11/19.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
54.
FOETAL MESENCHYMAL STEM CELL COMPOSITION OF ALLOGENIC ORIGIN, TREATMENT METHOD AND USE THEREOF IN MASTITIS IN MILK-PRODUCING ANIMALS, INCLUDING CATTLE
The present invention relates to the use of regenerative medicine in livestock farming, in particular to regenerative medicine for the care of livestock, and even more particularly to regenerative medicine in the care of milk-producing animals, including cattle. Specifically, the invention concerns a foetal mesenchymal stem cell (MSC) composition of allogenic origin, a treatment method and the use thereof in mastitis in milk-producing animals, including cattle, suffering from mastitis, to immunostimulate the animal, the MSC coming from foetal bovine adipose tissue. The composition can be administered via the intramammary route, exercising an immunomodulatory effect on the inflammatory response and strengthening antimicrobial activity against mastitis-causing pathogens in milk-producing animals with mastitis, thereby becoming an alternative to replacing and/or supplementing the use of antibiotics.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
This patent concerns a compact and portable system for real-time detection and location of electromagnetic emissions in the spectrum used by mobile devices (cell phones and Wi-Fi/Bluetooth devices). The principle of detection and location is based on phased array technology, which enables the synthesis of a directional radiation beam that can be electrically controlled in terms of both its shape and direction. This technology is used primarily in military and astronomical applications. The device also includes localization and control algorithms. This device will allow for detecting and locating electromagnetic emissions by means of an antenna beam scan within a field of view of 80×80 degrees. Once the detection and location have been established, the results are overlaid to a visual image captured by a video camera.
G01S 3/72 - Systèmes à diversité spécialement adaptés à la radiogoniométrie
G06T 11/20 - Traçage à partir d'éléments de base, p. ex. de lignes ou de cercles
G01S 3/78 - Radiogoniomètres pour déterminer la direction d'où proviennent des ondes infrasonores, sonores, ultrasonores ou électromagnétiques ou des émissions de particules sans caractéristiques de direction utilisant des ondes électromagnétiques autres que les ondes radio
56.
Metal-carbon structure hybrid formulation for dental use in the treatment of dental hypersensitivity, demineralization and cavities
The present invention relates to an antibacterial composition which, when applied to the surface of a tooth, allows remineralisation of the enamel to occur, said composition having very low toxicity for human use. When applied, the composition leaves no stains and does not alter the visible colour characteristics of the teeth to which it has been applied.
Cricetulus griseus genome, enriched in cytosine-guanine dinucleotides (RegCG). The first promoter can be upstream of a second promoter, cytomegalovirus (CMV) promoter. The invention also relates to vectors, transfected cellular lines and a method for producing RP in mammal cells that have been transfected with vectors containing said promoter or variants thereof.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
58.
AAV/UPR-plus virus, UPR-plus fusion protein, genetic treatment method and its use in treatment of neurodegenerative diseases, such as Parkinson's disease and Huntington's disease, among others
The present invention presents a sequence of the AAV/UPR-plus virus, a genetic treatment method and its use in the treatment of neurodegenerative diseases, such as Parkinson's and Huntington's diseases, among others, as presented in the in vitro studies shown in FIG. 14/17.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
59.
MIXTURE OF FUNGAL BIOCONTROLLERS FOR CONTROLLING FUNGI THAT CAUSE DEAD ARM OF GRAPEVINE
Trichoderma harzianum, Clonostachys roseaTrichoderma harzianum, Clonostachys rosea and an agronomically appropriate vehicle. The invention also relates to a method for preventing and controlling fungal diseases in plants, which comprises using said composition on a plant susceptible to developing a fungal infection.
SEQUENTIAL METHOD FOR CONSTRUCTING NANOPARTICLES OF METALLIC COPPER AND THE SUBSEQUENT DECORATION OR COATING THEREOF WITH SMALLER NANOPARTICLES OF SECONDARY METAL
The invention relates to a process for obtaining nanoparticles (NPs) of copper, specifically with a size between 10 nm and 50 nm. Specifically, a method is described for constructing NPs of metallic copper and subsequently decorating or coating with smaller NPs of secondary metal. Existing technologies for silicon-based solar cells use silver but never copper because the penetration of same into the substrate severely reduces the efficiency of the device. For electrical interconnections in microprocessors, other metals, mainly aluminium, are used, despite being less electrically conductive. Given the relatively high cost of silver, replacing silver with copper is economically interesting, especially if this also allows inkjet print technologies to be used.
B22F 9/20 - Fabrication des poudres métalliques ou de leurs suspensionsAppareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques solides
The present invention relates to a composition for repairing incipient tooth decay that comprises a matrix (preferably a gel) and nanoparticles included and/or dispersed in said matrix, where said matrix and said nanoparticles include silicon, calcium and phosphate ions; and a method for preparing said composition.
GEO ANANTARA PABLO WASHINGTON SILVA OSORIO EIRL (Chili)
UNIVERSIDAD DE CHILE (Chili)
Inventeur(s)
Duarte Mermoud, Manuel Armando
Silva Osorio, Pablo Washington
Abrégé
The invention relates to a system for tracking the trajectory of at least one means of transport (1), which maintains communication regardless of the effect of signal jammers (400), wherein the elements that are inside the tracked means of transport (1) comprise: at least one detachable communication means (103), located inside a container (102) and which is ejected from the means of transport via ejection means (101); a signal jammer detector (100) which communicates with the ejection means (101) to trigger the ejection of the detachable communication means (103); and power sources (200, 201) that power the signal jammer detector (100) and the ejection means (101); and in which the elements that are on the outside of the means of transport (1) comprise monitoring means (104) that track the detachable communication means (103); and a method for tracking the trajectory of at least one means of transport (1).
B60R 25/33 - Détection relative au vol ou autres événements relatifs aux systèmes antivol de la géo-localisation, p. ex. en fournissant les coordonnées de géo-localisation (GPS)
G08G 1/00 - Systèmes de commande du trafic pour véhicules routiers
63.
BIMETAL METHOD FOR CONSTRUCTING NANOPARTICLES (NPS) OF METALLIC COPPER FOR COATING WITH SMALLER NANOPARTICLES OF SECONDARY METAL
The invention relates to a process for obtaining nanoparticles (NPs) of copper, specifically with a size between 10 nm and 50 nm. Specifically, a method is described for constructing NPs of metallic copper and subsequently decorating or coating with smaller NPs of secondary metal. Existing technologies for silicon-based solar cells use silver but never copper because the penetration of same into the substrate severely reduces the efficiency of the device. For electrical interconnections in microprocessors, other metals, mainly aluminium, are used, despite being less electrically conductive. Given the relatively high cost of silver, replacing silver with copper is economically interesting, especially if this also allows inkjet print technologies to be used.
B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensionsAppareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p. ex. de solutions
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
64.
VACCINE FORMULATION FOR FISH BASED ON LIPID NANOVESICLES, PARTICULARLY A PROTEOLIPOSOME OR COCHLEATE, WITH ACTIVITY AGAINST SALMON RICKETTSIAL SYNDROME (SRS)
The invention relates to aquaculture. In particular, it relates to immunisation in fish farming. More particularly, the present invention relates to a vaccine formulation for fish, based on lipid nanovesicles with activity. Even more particularly, the present invention relates to a vaccine formulation for fish, based on lipid nanovesicles, especially a proteoliposome, with activity against salmon rickettsial syndrome (SRS)
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Ugni molinaeUgni molinae, Myrtaceae) containing bioactive compounds that prevent or attenuate the development of neurodegenerative diseases such as Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), which are progressive and debilitating incurable pathologies that affect a high percentage of the senior adult population. In particular, the present invention proposes the use of natural extracts of Chilean guava, which have strong neuroprotective activity. The invention proposes the use of natural extracts useful in diseases that are currently incurable and affect a high percentage of the population.
A61K 36/61 - Myrtaceae (famille du myrte), p. ex. cajeputier ou eucalyptus
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
66.
HUMAN ANTIBODY AND FRAGMENTS THEREOF FOR USE IN THE TREATMENT OF GASTRIC CANCER (GC) AND OTHER TYPES OF TUMOURS EXPRESSING THE MICA PROTEIN (MHC CLASS I CHAIN-RELATED PROTEIN A GENE)
A bivalent, anti-MICA human monoclonal antibody formed by two or more heavy and light chains with a variable immunoglobulin domain neutralises the MICA protein in its soluble state and opsonises tumour cells expressing the antigen, stimulating adaptive immunity in the treatment of gastric cancer or other types of cancer in which the tumour cells express MICA in the soluble form or abundantly on their surface.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
The present invention relates to a method for removing dyes from textile effluents and other organic substances using nanocomposites based on zinc hydroxides and carboxylic acids capable of adsorbing and degrading. More specifically, the present invention consists of a method to generate new zinc hydroxide-based materials, which allows removal and degradation of methylene blue and other organic compounds from wastewater from industrial effluents, particularly those from textile industry. In addition, nanocomposites are disclosed, laminar solids formed by the stacking of hybrid layers where each layer constitutes a structural unit, each unit is formed by two individual inorganic sheets of zinc hydroxide whose X-ray diffraction pattern presents a reflection 001 in the range 2 teta (2θ) between 2 ° and 10 °.
The present invention relates to a method for removing dyes from textile effluents and other organic substances using nanocomposites based on zinc hydroxides and carboxylic acids capable of adsorbing and degrading. More specifically, the present invention consists of a method to generate new zinc hydroxide-based materials, which allows removal and degradation of methylene blue and other organic compounds from wastewater from industrial effluents, particularly those from textile industry.
B01J 31/04 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des composés organiques ou des hydrures métalliques contenant des acides carboxyliques ou leurs sels
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
The invention relates to a bidirectional tuned mass damper (BTMD) based on multiple composite levers, in which a mass (1) controls the vibration of a structure (9). According to the invention, the mass (1) of the damper is connected to the structure (9) by means of primary levers (2) and secondary levers (3), the primary lever (2) is connected to the structure (9) by means of a first pivot point (4), the primary lever (2) is connected to the secondary lever (3) by means of a second pivot (5), the secondary lever (3) is connected to the mass (1) by means of a third pivot (6), and springs (7) and shock absorbers (8) are connected between the mass (1) of the damper and the primary lever (3).
E04B 1/98 - Protection contre d'autres agents indésirables ou dangers contre les vibrations ou les chocsProtection contre d'autres agents indésirables ou dangers contre les destructions mécaniques, p. ex. par les raids aériens
E04H 9/02 - Bâtiments, groupes de bâtiments ou abris conçus pour résister à des situations extérieures anormales, p. ex. à des bombardements, à des séismes ou à des climats extrêmes, ou pour se protéger de ces situations résistant aux séismes ou à l'effondrement du sol
E04B 1/36 - Appuis ou autres supports permettant le mouvement
F16F 7/10 - Amortisseurs de vibrationsAmortisseurs de chocs utilisant un effet d'inertie
F16F 7/104 - Amortisseurs de vibrationsAmortisseurs de chocs utilisant un effet d'inertie l'élément d'inertie étant monté de manière élastique
F16F 15/02 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif
F16F 15/04 - Suppression des vibrations dans les systèmes non rotatifs, p. ex. dans des systèmes alternatifsSuppression des vibrations dans les systèmes rotatifs par l'utilisation d'organes ne se déplaçant pas avec le système rotatif utilisant des moyens élastiques
70.
Bactericide composition based on a mixture of bacteriophages for the control of black plague in plants or parts thereof, preferably the walnut, caused by Xanthomonas arboricola pv. juglandis; preparation method and application
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
A01N 25/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des ingrédients stabilisant les ingrédients actifs
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
The present invention relates to a method for obtaining nanostructures, specifically nanoemulsions and nanocapsules of carotenoids such as curcumin and astaxanthin, which method, using particular concentrations of the ingredients forming the nanostructures, allows high charges of the active ingredient in the nanostructures containing said ingredients and protection of said nanostructures from environmental factors such as oxidation and light. The invention also relates to the nanoemulsions and nanocapsules of curcumin and astaxanthin for use in the food, pharmaceutical and cosmetics industries, among others.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
Staphylococcus aureus, which causes periprosthetic infections. This removable dental material allows for the production of a new dental device to prevent and/or control oral infections caused by said pathogens, such as denture stomatitis, secondary caries, periodontal diseases, among others.
A61K 6/70 - Préparations pour la technique dentaire comprenant des additifs inorganiques
A61K 6/887 - Composés obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone
A01N 55/02 - Biocides, produits repoussant ou attirant les animaux nuisibles ou régulateurs de croissance des végétaux, contenant des composés organiques comportant des éléments autres que le carbone, l'hydrogène, les halogènes, l'oxygène, l'azote et le soufre contenant des atomes de métal
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The invention relates to a method for the cultivation of chimeric macroalgae, in particular of brown algae, wherein the chimeric individuals are obtained in a laboratory and subsequently transferred to their final habitat. The chimeric macroalgae are advantageous in terms of their rate of growth and greater resistance to extreme environmental conditions than non-chimeric algae, as a result of which, the method according to the invention is particularly useful for the commercial cultivation of these algae or for the recolonisation of areas where the natural population of these algae has diminished significantly.
The invention relates to: a system for the production of carbon nanotubes based on carbonaceous matter, preferably, plastic waste and solar energy; and a production method
B29B 17/04 - Désintégration des matières plastiques
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
C10B 49/00 - Distillation destructive des matières carbonées solides par chauffage direct au moyen d'agents porteurs de chaleur, y compris la combustion partielle de la matière à traiter
B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage utilisant des radiations électromagnétiques
F24S 20/20 - Collecteurs de chaleur solaire pour recevoir de l’énergie solaire concentrée, p. ex. récepteurs pour centrales électriques solaires
F24S 23/30 - Agencements pour concentrer les rayons solaires pour les collecteurs de chaleur solaire avec des lentilles
F24S 30/40 - Agencements pour mouvoir ou orienter des modules de collecteurs de chaleur solaire pour le déplacement en rotation
F24S 30/45 - Agencements pour mouvoir ou orienter des modules de collecteurs de chaleur solaire pour le déplacement en rotation avec deux axes de rotation
F24S 50/20 - Agencements pour commander les collecteurs de chaleur solaire pour le suivi
76.
System and method for secure electronic communications through security hardware based on threshold cryptography
The present application is directed to a method and system for secure electronic communications using physically distributed security hardware and capable of operating by simulating a common or unitary HSM device. This is achieved by implementing the internal operations of the HSM using threshold cryptography on a set of internal nodes. In order to provide the necessary functionality, the keys and the required operations (such as the digital signature) are distributed among these nodes. In particular, the system provides digital signature capabilities through an efficient and modular application of Victor Shoup's schema referred to in the background. The digital signature process involves the steps of: 1) the signing agent receives a document to be signed and the alias of the key with which the document will be signed; 2) the signing agent place the document in the request queue; 3) the active nodes retrieve the request from the queue; 4) each node signs the request with its piece of key; 5) each node puts its partial signature in the response queue; 6) the signing agent receives the partial signatures and verifies them; 7) if at least k>n/2 valid partial signatures are received, the signature is validated and delivered to the client. Otherwise, an error message is generated.
H04L 29/06 - Commande de la communication; Traitement de la communication caractérisés par un protocole
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
77.
Method for the early detection of acute kidney injury in critical patients, using fibroblast growth factor 23, klotho and erythropoietin as biomarkers
The invention is an ex vivo method for early detection of acute kidney injury in critical patients, which includes the measurements of fibroblast growth factor 23 (FGF23), klotho (KL) and erythropoietin (EPO) as biomarkers. These measurements are obtained from a venous blood sample or urine, and allow the determination of the following indicators: 1=([FGF23]p×[EPO]p); 2=([FGF23]p/[Klotho]p); 3=([EPO]p)/[Klotho]p); 4=([FGF23]p×[EPO]p)/[Klotho]p); where [X]p is defined as the plasma level of a specific molecule (X) which includes fibroblast growth factor 23 (FGF23), klotho (KL) or erythropoietin (EPO). If the value of the indicator 1, 2, 3, 4 or two or more thereof, is equal or higher than a cut-off point (10 U), the indicator and/or indicators allow the identification of patients with high risk of developing AKI, with a high sensitivity/specificity. Therefore high levels of the indicator are associated to a high probability of the presence/development of AKI, which allows to perform specific clinical interventions for patients with AKI. If the value of the indicator 1, 2, 3, 4 or two or more thereof, is lower than the previously mentioned cut-off point, the probability of presence/development of AKI is low, therefore patients require only standard treatment.
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
G01N 33/493 - Analyse physique de matériau biologique de matériau biologique liquide d'urine
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
78.
Control system and procedure for controlled access by means of an optical device based on flat bands
A control system for controlled access to a user by means of verifying a physical element defined in an optical and low level of power context, which includes: a setup (1) for the creation of arbitrary spatial light patterns, with control of amplitude and phase; which includes: a source of light (9) which emits a Laser beam; toward a first microscope objective (11); a spatial light modulation set (2) which receives the light of the first microscope objective (11) and said spatial light modulator set (2) sends a profile modulated in amplitude and phase which form an image to a beam splitter BS (17) which divides the image into an initial CCD camera (6) and to a second microscope objective (12); a defined physical element (7) which receives the initial image from the second microscope objective (12), and transmits the image without diffracting it as a final image to a third microscope objective (13); a final CCD camera (8), that receives the final image of the third microscope objective (13) and sends it to a computer (300) which compares that final image with the initial image, and performs a calculation of similarity between both images to decide to grant access to the user, if the similarity is greater than a predefined value, and deny it if the similarity is less than a predefined value; a control procedure of controlled access which compares a pattern of dots transmitted through the defined physical element, which code the numbers 0 to 9 and decides to grant or deny access if it matches with the key entered by user.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
G02B 6/122 - Éléments optiques de base, p. ex. voies de guidage de la lumière
G06K 19/00 - Supports d'enregistrement pour utilisation avec des machines et avec au moins une partie prévue pour supporter des marques numériques
G06K 7/10 - Méthodes ou dispositions pour la lecture de supports d'enregistrement par radiation électromagnétique, p. ex. lecture optiqueMéthodes ou dispositions pour la lecture de supports d'enregistrement par radiation corpusculaire
G06K 19/06 - Supports d'enregistrement pour utilisation avec des machines et avec au moins une partie prévue pour supporter des marques numériques caractérisés par le genre de marque numérique, p. ex. forme, nature, code
H04N 9/31 - Dispositifs de projection pour la présentation d'images en couleurs
79.
Curcumin-loaded nanoemulsions, method of manufacture, and method of preventive treatment using the same
A oil-in-water curcumin nanoemulsion that includes curcumin dissolved in at least one miscible solvent and encapsulated in an oil core, wherein the oil core also comprises a stabilizer, wherein the oil core forms an organic phase which is dispersed in an aqueous solvent, and wherein the oil core is selected from a pharmaceutically acceptable oil. A method of manufacturing an oil-in-water curcumin nanoemulsion includes dissolving the curcumin in at least one miscible solvent; encapsulating the curcumin in the oil core to produce an organic phase solution; adding the stabilizer to the organic phase solution; dispersing the organic phase solution in the aqueous solvent; and evaporating the mixture. A method of preventing metastatic cancer using an oil-in-water curcumin nanoemulsion by administering an amount of the nanoemulsion topically to an area of an excised primary tumor, and monitoring any reincidence of metastatic cancer in the excised primary tumor area.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
80.
BRACING WITH RESTRICTED BUCKLING, MAKING IT POSSIBLE TO REDUCE THE SECTIONS OF DIAGONAL ELEMENTS OF BRACED FRAMES, AVOIDING GENERAL BUCKLING IN THE ELEMENT AND DISSIPATING ENERGY, AND USE THEREOF
The invention relates to a bracing with restricted buckling (1), for transferring force through the steel core, which provides a structure and dissipates energy, making it possible to reduce the sections of diagonal elements of braced frames, thus reducing construction costs without affecting the mechanical strength and thereby avoiding general buckling in the element via a confining material (2), which comprises: a core (3); a confining material (2); fastening means located at the ends of the core (3), wherein said confining material (2) covers the core (3), wherein said confining material (2) is arranged along the core (3) and is made from an elastomer material, which maintains constant strength in each cycle; and an outer jacket (4) which covers the confining material (2), and the use thereof.
E04B 1/00 - Constructions en généralStructures qui ne sont limitées ni aux murs, p. ex. aux cloisons, ni aux planchers, ni aux plafonds, ni aux toits
E04B 1/92 - Protection contre d'autres agents indésirables ou dangers
E04B 1/98 - Protection contre d'autres agents indésirables ou dangers contre les vibrations ou les chocsProtection contre d'autres agents indésirables ou dangers contre les destructions mécaniques, p. ex. par les raids aériens
81.
MAGNETO-CENTRIFUGAL FLOTATION CELL FOR CONCENTRATING MATERIALS WHICH REDUCES WATER CONSUMPTION
The invention relates to a magneto-centrifugal flotation cell for ore concentration which reduces water consumption. A disadvantage of conventional flotation cells is the use of a large amount of water, some flotation cells requiring at least 60% water. The present invention uses ore pulp with increased density and viscosity, owing to the application of an axial magnetic field, wherein the Lorentz force, which is the force exerted by an electromagnetic field that receives a charged particle or an electrical current, can be used. The solution is a cell which, in addition to the forces that usually act on conventional flotation cells, uses external forces which, in principle, produce synergy in the separation of ore particles that have different gravitational and magnetic properties.
B03C 1/02 - Séparation magnétique agissant directement sur la substance à séparer
B03C 1/023 - Séparation utilisant les forces de Lorentz, c.-à-d. déviation de particules chargées électriquement dans un champ magnétique
B03C 1/08 - Séparation magnétique agissant directement sur la substance à séparer ayant des supports pour le matériau traité, en forme de plateaux, ou constitués par des tables avec des aimants fixes
B03C 1/10 - Séparation magnétique agissant directement sur la substance à séparer ayant des supports pour le matériau traité, de forme cylindrique
B03C 1/033 - Éléments constitutifsOpérations auxiliaires caractérisés par le circuit magnétique
B03C 1/247 - Séparation magnétique agissant directement sur la substance à séparer le matériau étant déplacé sous l'effet de champs oscillantsSéparation magnétique agissant directement sur la substance à séparer le matériau étant déplacé sous l'effet de champs mobiles, p. ex. générés par des bobines magnétiques stationnairesSéparateurs à champ de Foucault, p. ex. à rampe glissante le matériau étant déplacé sous l'effet de champs mobiles obtenus par rotation d'un tambour magnétique
A oil-in-water curcumin nanoemulsion that includes curcumin dissolved in at least one miscible solvent and encapsulated in an oil core, wherein the oil core also comprises a stabilizer, wherein the oil core forms an organic phase which is dispersed in an aqueous solvent, and wherein the oil core is selected from a pharmaceutically acceptable oil. A method of manufacturing an oil-in-water curcumin nanoemulsion includes dissolving the curcumin in at least one miscible solvent; encapsulating the curcumin in the oil core to produce an organic phase solution; adding the stabilizer to the organic phase solution; dispersing the organic phase solution in the aqueous solvent; and evaporating the mixture. A method of preventing metastatic cancer using an oil-in-water curcumin nanoemulsion by administering an amount of the nanoemulsion topically to an area of an excised primary tumor, and monitoring any reincidence of metastatic cancer in the excised primary tumor area.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
83.
SYSTEM FOR CONTAINING SPILLAGES FROM A TUBE TRANSPORTING FLUID OR MUD ACROSS DISTANCES OF SEVERAL KILOMETRES
The invention relates to a system for containing spillages from a tube (20) transporting fluid or mud across distances of several kilometres, in the mining, oil and/or sanitation industries, for containing a leaked fluid at a pressure in the order of atmospheric pressure, which system comprises modular chambers (11, 11') arranged in a chain or series along the tube (20), wherein each modular chamber (11, 11') is arranged around a corresponding section of the tube and comprises an upper module and a lower module which are complementary, for surrounding the tube, each module having a surrounding of plastic material and containing a filling material (7) that constitutes a porous medium, such that the leaked fluid or a portion of same, which enters through a perforation made by the tube breaking in the surrounding, can flow through the filling material (7). According to the invention, each upper module is in fluid communication with the lower module of the same modular chamber by run-off means, so that when a break in the tube projects the fluid inside the upper module, the liquid can run towards the lower module, each modular chamber being in fluid connection with contiguous modular chambers by means of flexible tubes (13) connected between the corresponding lower modules to allow evacuation by means of overflow, the upper module comprising a ventilation outlet (12) to evacuate a volume of air.
F17D 5/02 - Prévention, interception ou localisation des pertes
F17D 5/04 - Prévention, interception ou localisation des pertes au moyen d'un fluide signalisateur contenu dans une double paroi
B65D 61/02 - Châssis tubulaires avec jonctions élastiques
G01M 3/26 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation d'un fluide ou en faisant le vide par mesure du taux de perte ou de gain d'un fluide, p. ex. avec des dispositifs réagissant à la pression, avec des indicateurs de débit
84.
PEPTIDE SEQUENCE OF A GUIDE PROTEIN FOR THE PRODUCTION OF A PEPTIDE OF INTEREST, AN EXPRESSION VECTOR, A HOST CELL, AND A METHOD FOR THE PRODUCTION OF A PEPTIDE OF INTEREST
The invention relates to a peptide sequence of a guide protein for the production of a peptide of interest; a peptide sequence with a degree of similarity of at least 90% with the former; a nucleotide sequence which codifies for said guide protein; an expression vector comprising said nucleotide sequence; a host cell that expresses a fusion protein comprising a peptide of interest; and a method for producing a peptide of interest comprising the following steps: A) constructing an expression vector; B) inserting the expression vector into a host cell; C) expressing the fusion protein, cultivating the host cell in a culture medium; D) recovering the fusion protein accumulated in the host cell; E) separating the fusion protein; and F) purifying the peptide of interest.
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/67 - Méthodes générales pour favoriser l'expression
85.
NATURAL BIOSTIMULANT COMPOSITION FOR IMPROVING AGRICULTURAL PRODUCTION AND METHOD FOR APPLYING AND USING SAME TO INCREASE THE NUMBER OF ROOTS IN PLANTS
The invention relates to a natural biostimulant composition for improving agricultural production, specifically to a biostimulant composition for plants which contains lipoic acid and which is unknown in the prior art, and to a method for applying and using same to improve agricultural production, which allows the number of roots of the plant to be increased, thereby allowing better use of the nutritional value of soils. In this way, agricultural production in respect of the plant is maintained or even improved, without the need for excessive application of fertilisers and/or with more efficient use of water.
A01N 43/26 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec plusieurs hétéro-atomes des cycles à cinq chaînons
C07D 339/04 - Cycles à cinq chaînons comportant les hétéro-atomes en positions 1, 2, p. ex. acide lipoïque
The present patent relates to a compact, portable system that allows the real-time detection and location of electromagnetic emissions in the spectrum used by mobile devices (mobile phones and Wi-Fi/Bluetooth devices). The detection and location principle is based on phase-adjustment technology, which allows the synthesis of a directive beam of radiation, the shape and direction of which can be controlled electrically. This technology is used mainly in military and astronomical applications. The device also includes location and control algorithms. This device allows the detection and location of electromagnetic emissions by the antenna beam sweeping in a field of vision of 80x80 degrees. Once the detection and location have taken place, it is superimposed on a visual image collected by a video camera.
The invention relates to the expression of two molecules in viral vectors AAV/IGF2-HA and AAV/IGF2, the associated method and use thereof in the amelioration of protein misfolding-related diseases, such as Huntington's disease, as presented in the in vivo models in figure 11/19.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A new and distinct plum variety is described. ‘Sweet Pekeetah’ is an Asian plum variety with unique traits, as extremely late blooming and ripening dates. The flesh of ‘Sweet Pekeetah’ has crunchy texture, green color and soluble solids concentration reaches 20-22%, with upstanding sensory quality. The postharvest life potential of ‘Sweet Pekeetah’ can last 60 days keeping the original high sensory quality.
The present invention relates to an antibacterial composition which, when applied to the surface of a tooth, allows remineralisation of the enamel to occur, said composition having very low toxicity for human use. When applied, the composition leaves no stains and does not alter the visible colour characteristics of the teeth to which it has been applied.
The present invention relates to the medical industry. In particular, the invention relates to a functionalised polyvinyl chloride (PVC) polymer for medical use, which is flexible and compatible with blood. The invention relates specifically to a biomolecule-functionalised PVC and to the production method thereof, for the purpose of producing a flexible, blood-compatible polymer for use in medicine.
A new and distinct variety of nectarine tree named “Andes Nec-4” which has fruit that is similar to the ‘6B-170’ nectarine that is white in flesh color. The variety is distinguished from the ‘6B-170’ by reaching out higher content of soluble solids, by more extended red blush of the nectarine surface, by slower pulp softening rate during the last two weeks before the commercial harvest, by a higher postharvest life potential, and by a balanced acid/sweet flavor. ‘Andes Nec-4’ can maintain its quality after 40 days in cold storage.
The present invention relates to the field of genetic engineering, preferably the expression of recombinant proteins (RP). In particular, the invention relates to a promoter and variants thereof having an equal function and more than 90% sequence identity. The promoter comprises a fragment of 1147 base pairs (bp) of a first promoter, promoter of the β-actin gene of the Cricetulus griseus genome, which rich in cytosine-guanine (RegCG). The first promoter can be upstream of a second promoter, cytomegalovirus (CMV) promoter. The invention also relates to vectors, transfected cellular lines and a method for producing RP in mammal cells that have been transfected with vectors containing said promoter or variants thereof.
This invention presents a sequence of the virus AAV/XBP1s-HA, method and its use in the improvement of cognitive functions, of memory and of learning, as presented in the in vivo studies in FIG. 12/17 right panel.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The invention relates to multi-wall carbon nanotubes (MWCNT) for the adsorption of molecular hydrogen, a method for producing the nanotubes via aerosol-assisted chemical vapour deposition (AACVD), using magnetite with a purity of ᡶ85% as a mineral catalyst, and a method for purifying said nanotubes in order to increase their capacity for hydrogen adsorption.
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B82Y 40/00 - Fabrication ou traitement des nanostructures
C01B 3/00 - HydrogèneMélanges gazeux contenant de l'hydrogèneSéparation de l'hydrogène à partir de mélanges en contenantPurification de l'hydrogène
C23C 16/00 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD]
C23C 16/44 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement
C23C 16/448 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour produire des courants de gaz réactifs, p. ex. par évaporation ou par sublimation de matériaux précurseurs
C23C 16/458 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour supporter les substrats dans la chambre de réaction
D01F 11/00 - Post-traitement chimique de filaments, ou similaires, faits par l’homme, pendant leur fabrication
D01F 11/10 - Post-traitement chimique de filaments, ou similaires, faits par l’homme, pendant leur fabrication de carbone
D01F 11/12 - Post-traitement chimique de filaments, ou similaires, faits par l’homme, pendant leur fabrication de carbone avec des substances inorganiques
D01F 9/00 - Filaments, ou similaires, faits par l’homme, formés d’autres substancesLeur fabricationAppareils spécialement adaptés à la fabrication de filaments de carbone
D01F 9/12 - Filaments de carboneAppareils spécialement adaptés à leur fabrication
95.
EDIBLE BIO-ACTIVE FILMS BASED ON CHITOSAN OR A MIXTURE OF QUINOA PROTEIN-CHITOSAN; SHEETS HAVING CHITOSAN-TRIPOLYPHOSHATE-THYMOL NANOPARTICLES; PRODUCTION METHOD; BIO-PACKAGING COMPRISING SAME; AND USE THEREOF IN FRESH FRUIT WITH A LOW PH
The invention relates to edible bio-active films comprising: a matrix material such as a sheet of paper formed by chitosan of a high molecular weight or a mixture of high-molecular-weight chitosan and an aqueous extract of extracted quinoa proteins at pH 11; and one or more layers of a composition of a printable suspension of nanoparticles, formed by a solution of low-molecular-weight chitosan and thymol with sodium tripolyphosphate dispersed in glycerol. The invention also relates to: a method for preparing said edible bio-active films; the use of the edible bio-active films; bio-packaging comprising same; method for creating said bio-packaging; and the use thereof.
A23B 4/10 - Recouvrement à l'aide d'une couche protectriceCompositions ou appareils à cet effet
B32B 7/06 - Liaison entre couches permettant une séparation sans difficultés
B32B 9/02 - Produits stratifiés composés essentiellement d'une substance particulière non couverte par les groupes comprenant des substances animales ou végétales
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
96.
PHARMACEUTICAL FORM FOR ORAL ADMINISTRATION OF A HIGHLY CONTROLLED AND STABLE DOSE OF NANOPARTICLES OR BIOMACROMOLECULE SUSPENSIONS
The invention relates to the pharmaceutical industry, particularly to the pharmaceutical industry related to drugs comprising biomacromolecules, or biopharmaceuticals. Even more particularly, the invention relates to a pharmaceutical form comprising biomacromolecules such as lymphokines, hormones, haematopoietic factors, growth factors, antibodies, enzymes, inhibitors, vaccines, and DNA or RNA derivatives. The invention provides a pharmaceutical form comprising biomacromolecules and a method for producing same based on inkjet printing using inks formed by nanosystems comprising the biomacromolecule(s), the drug or biopharmaceutical being administered orally. Even more particularly, the invention relates to a pharmaceutical form for oral administration of a highly controlled, stable controlled release dose of a biomacromolecule comprising: a) a polymer film as a printing substrate, formed by at least one pharmaceutically acceptable excipient; and b) an inkjet ink printed on the polymer film and comprising nanoparticles or nanoparticle suspensions comprising the biomacromolecule and at least one pharmaceutically acceptable excipient.
The invention relates to a method and a system for carrying out secure electronic communications by means of physically distributed security hardware that can simulate a common or single HSM device. This is achieved by implementing the internal operations of the HSM using threshold cryptography on a group of internal nodes. In order to provide the necessary functionality, the required codes and operations (such as the digital signature) are distributed between said nodes. In particular, the system provides digital signature capacities via an efficient and modular application of the Victor Shoup model referred to in the prior art. The digital signature process involves the following steps: 1) the signing agent receives a document to sign and the alias of the code with which the document will be signed; 2) the signing agent puts the document in the queue of requests; 3) the active nodes retrieve the request from the queue; 4) each node signs the request with its section of the code; 5) each node puts its partial signature in the response queue; 6) the signing agent receives the partial signatures and verifies them; and 7) if at least k ᡶ n / 2 valid partial signatures are received, the signature is validated and is delivered to the client. If not, an error message is generated.
The invention relates to a nucleic acid molecule that codes for a poligalacturonase that is highly efficient at low temperatures between 5°C - 15°C, and the coded enzyme. The invention also relates to vectors, host cells, recombination methods for producing said enzyme, as well as compositions comprising the poligalacturonase. The invention further relates to the use of said enzyme in the degradation of pectin during the production of wine, beer or fruit juice and in the clarification of grape must or fruit juice.
C12N 15/81 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour champignons pour levures
99.
BACTERICIDE COMPOSITION BASED ON A MIXTURE OF BACTERIOPHAGES FOR THE CONTROL OF BLACK PLAGUE IN PLANTS OR PARTS THEREOF, PREFERABLY THE WALNUT, CAUSED BY XANTHOMONAS ARBORICOLA PV. JUGLANDIS; PREPARATION METHOD AND APPLICATION
The invention relates to a bactericide composition based on bacteriophages for the control of black plague in plants or parts thereof, preferably walnuts, a preparation method and application. The invention provides methods for the isolation, propagation and application of bacteriophages against phytopathogens affecting trees/plants that are of commercial interest for their fruit, flowers etc., for the prevention, treatment or reduction of signs, in particular, for Xanthomonas a. pv juglandis in walnuts.
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
100.
METHOD FOR PRODUCING ORTHOPAEDIC AND DENTAL ACRYLIC MATERIALS HAVING ANTIMICROBIAL PROPERTIES, USING COPPER NANOPARTICLE TECHNOLOGY
The invention relates to a novel biomaterial for the production of antimicrobial dental devices for use in controlling the growth of microorganisms in the oral cavity, such as removable dentures, using copper nanoparticle technology, having antimicrobial properties against dental pathogens, such as Candida albicans, the pathogen responsible for denture stomatitis, Streptococcus mutans, the pathogen responsible for the onset and progression of cavity formation, as well as Staphylococcus aureus which causes periprosthetic infections. According to the invention, the removable dental material can be used to produce a novel dental device for preventing and/or controlling oral infections caused by the aforementioned pathogens, such as, inter alia, denture stomatitis, secondary caries, and periodontal diseases.
A01N 55/02 - Biocides, produits repoussant ou attirant les animaux nuisibles ou régulateurs de croissance des végétaux, contenant des composés organiques comportant des éléments autres que le carbone, l'hydrogène, les halogènes, l'oxygène, l'azote et le soufre contenant des atomes de métal
A61K 6/08 - Emploi de résines naturelles ou synthétiques
